• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Apyx Medical Corporation (Amendment)

    2/14/24 7:32:58 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care
    Get the next $APYX alert in real time by email
    SC 13G/A 1 p24-0394sc13ga.htm APYX MEDICAL CORPORATION

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
     
    SCHEDULE 13G/A
     
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 6)*
     

    Apyx Medical Corporation

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    03837C106

    (CUSIP Number)
     

    December 31, 2023

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G/A is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 03837C10613G/APage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    1,025,963 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    1,025,963 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,025,963 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.0%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. 03837C10613G/APage 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong, M.D.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    1,025,963 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    1,025,963 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,025,963 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.0%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. 03837C10613G/APage 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Apyx Medical Corporation (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 5115 Ulmerton Road, Clearwater, FL 33760.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by:

     

      (i) RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the RTW Funds; and
         
      (ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:

     

      RTW Investments is a Delaware limited partnership.  Dr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the "Shares").

     

     

    CUSIP No. 03837C10613G/APage 5 of 7 Pages

     

    Item 2(e). CUSIP NUMBER:
       
      03837C106

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                             

     

    Item 4. OWNERSHIP:

     

        The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
         
        The percentages set forth herein are calculated based upon 34,643,855 Shares outstanding as of November 8, 2023 as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 9, 2023.

     

     

    CUSIP No. 03837C10613G/APage 6 of 7 Pages

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following:  ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2.  The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 03837C10613G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    DATED:  February 14, 2024
     
    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong, M.D.  
    Name: Roderick Wong, M.D.  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong, M.D.  
    RODERICK WONG, M.D.  
         

     

     

    Get the next $APYX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APYX

    DatePrice TargetRatingAnalyst
    10/17/2024Neutral
    BTIG Research
    7/14/2023$8.00Overweight
    Stephens
    5/20/2022$12.00Buy
    Lake Street
    8/13/2021$12.00 → $14.00Market Outperform
    JMP Securities
    More analyst ratings

    $APYX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Apyx Medical Corporation Reports First Quarter 2025 Financial Results

      Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last yearU.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last yearPreparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearanceManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its first quarter ended March

      5/8/25 7:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation Announces Two Peer-Reviewed Publications on the Use of Renuvion in Abdominal Body Contouring Procedures

      Two studies report favorable clinical outcomes and safety data for Renuvion® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients seeking treatment for loose and lax skin CLEARWATER, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform marketed and sold as Renuvion®, today announced the publication of two peer-reviewed clinical studies evaluating the use of Renuvion during body contouring procedures that also included lipoabdominopla

      4/29/25 8:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

      CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 63341. Partic

      4/24/25 8:45:51 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Apyx Medical Corporation

      10-Q - Apyx Medical Corp (0000719135) (Filer)

      5/8/25 12:27:23 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Apyx Medical Corp (0000719135) (Filer)

      5/8/25 6:58:22 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Apyx Medical Corp (0000719135) (Filer)

      4/29/25 8:12:02 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Apyx Medical Corporation

      SC 13G - Apyx Medical Corp (0000719135) (Subject)

      10/31/24 5:44:01 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Apyx Medical Corporation

      SC 13G/A - Apyx Medical Corp (0000719135) (Subject)

      10/15/24 9:18:53 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Apyx Medical Corporation (Amendment)

      SC 13D/A - Apyx Medical Corp (0000719135) (Subject)

      5/9/24 7:45:22 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Hill Matthew C bought $6,780 worth of shares (6,000 units at $1.13), increasing direct ownership by 240% to 8,500 units (SEC Form 4)

      4/A - Apyx Medical Corp (0000719135) (Issuer)

      3/3/25 4:05:12 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Hill Matthew C bought $6,030 worth of shares (5,336 units at $1.13), increasing direct ownership by 213% to 7,836 units (SEC Form 4)

      4 - Apyx Medical Corp (0000719135) (Issuer)

      8/13/24 6:56:00 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Hill Matthew C bought $5,475 worth of shares (2,500 units at $2.19) (SEC Form 4)

      4 - Apyx Medical Corp (0000719135) (Issuer)

      12/14/23 9:00:19 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    Leadership Updates

    Live Leadership Updates

    See more
    • Apyx Medical Corporation Announces Board Leadership Transition

      Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

      5/9/24 7:00:00 AM ET
      $APYX
      $BVS
      $XTNT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

      Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

      11/28/23 8:30:00 AM ET
      $APYX
      $PDSB
      $SSKN
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

      NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an

      3/1/22 4:05:00 PM ET
      $APYX
      $LNTH
      $PRTK
      $SCPH
      Medical/Dental Instruments
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Biotechnology: Pharmaceutical Preparations

    $APYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Hill Matthew C bought $6,780 worth of shares (6,000 units at $1.13), increasing direct ownership by 240% to 8,500 units (SEC Form 4)

      4/A - Apyx Medical Corp (0000719135) (Issuer)

      3/3/25 4:05:12 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Roman Shawn David

      4 - Apyx Medical Corp (0000719135) (Issuer)

      1/17/25 4:07:08 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Baylor-Henry Minnie

      4 - Apyx Medical Corp (0000719135) (Issuer)

      1/17/25 4:07:05 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Apyx Medical

      BTIG Research initiated coverage of Apyx Medical with a rating of Neutral

      10/17/24 7:28:31 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Stephens initiated coverage on Apyx Medical with a new price target

      Stephens initiated coverage of Apyx Medical with a rating of Overweight and set a new price target of $8.00

      7/14/23 7:29:43 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Apyx Medical with a new price target

      Lake Street initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $12.00

      5/20/22 8:54:50 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    Financials

    Live finance-specific insights

    See more
    • Apyx Medical Corporation Reports First Quarter 2025 Financial Results

      Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last yearU.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last yearPreparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearanceManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its first quarter ended March

      5/8/25 7:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

      CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 63341. Partic

      4/24/25 8:45:51 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025

      CLEARWATER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2024 will be released before the market opens on Thursday, March 13th. Management will host a conference call at 8:30 a.m. Eastern Time on Thursday, March 13th to discuss the results of the fourth quarter and fiscal year 2024, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international call

      2/27/25 8:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care